PDC*line Pharma, a clinical stage biotech company developing cancer vaccines, has completed its Series B2 round of financing, raising a total of €17.5m (US$20.3m) with Belgian and South-Korean investors.
Sotio has selected local CRO Accord Research to carry out Phase I/II trials on its dendritic cell vaccines to treat patients with lung cancer in the Czech Republic.